Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Boceprevir

FDA-approved product (capsule, oral), marketed as Victrelis.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Boceprevir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis C virus infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antivirals for treatment of hcv infections
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AP03

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Boceprevir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Boceprevir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)

    NCT00845065 · start 2009-02

    Registered record
    Registry ID
    NCT00845065
    Conditions
    Hepatitis C, Chronic
    Interventions
    Boceprevir; Placebo; Peginterferon alfa-2a; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-02
    Completion
    2010-10
    Enrolment
    202

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic
    InterventionBoceprevir; Placebo; Peginterferon alfa-2a; Ribavirin
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)

    NCT00705432 · start 2008-08

    Registered record
    Registry ID
    NCT00705432
    Conditions
    Hepatitis C, Chronic
    Interventions
    Peginterferon alfa-2b (PEG); Ribavirin (RBV); Placebo; Boceprevir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-08
    Completion
    2010-05
    Enrolment
    1,472

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic
    InterventionPeginterferon alfa-2b (PEG); Ribavirin (RBV); Placebo; Boceprevir
    PhasePhase 3
    Registry statusCompleted

  • Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)

    NCT00708500 · start 2008-08

    Registered record
    Registry ID
    NCT00708500
    Conditions
    Hepatitis C, Chronic
    Interventions
    Boceprevir (SCH 503034); Pegylated interferon alfa-2b (SCH 54031); Ribavirin (SCH 18908); Boceprevir placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-08
    Completion
    2010-04
    Enrolment
    404

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic
    InterventionBoceprevir (SCH 503034); Pegylated interferon alfa-2b (SCH 54031); Ribavirin (SCH 18908); Boceprevir placebo
    PhasePhase 3
    Registry statusCompleted

  • Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)

    NCT00689390 · start 2007-02-20

    Registered record
    Registry ID
    NCT00689390
    Conditions
    Hepatitis C, Chronic; Hepacivirus
    Interventions
    Boceprevir; Narlaprevir; Peginterferon alfa-2b; Ribavirin; Blood/Plasma Collection
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2007-02-20
    Completion
    2014-10-13
    Enrolment
    1,954

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic; Hepacivirus
    InterventionBoceprevir; Narlaprevir; Peginterferon alfa-2b; Ribavirin +1 more
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)

    NCT00160251 · start 2005-09

    Registered record
    Registry ID
    NCT00160251
    Conditions
    Chronic Hepatitis C
    Interventions
    Boceprevir (BOC); PegIntron (PEG); Ribavirin (RBV)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-09
    Completion
    2007-07
    Enrolment
    357

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    InterventionBoceprevir (BOC); PegIntron (PEG); Ribavirin (RBV)
    PhasePhase 2
    Registry statusCompleted